ANI Pharmaceuticals, Inc.
ANIP
$82.10
-$0.58-0.70%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.58% | 53.12% | 43.43% | 44.75% | 12.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.58% | 53.12% | 43.43% | 44.75% | 12.52% |
| Cost of Revenue | 48.06% | 36.97% | 48.58% | 56.32% | 31.13% |
| Gross Profit | 57.67% | 63.65% | 40.57% | 36.86% | 1.83% |
| SG&A Expenses | 10.08% | 65.05% | 57.49% | 56.36% | 64.91% |
| Depreciation & Amortization | 43.71% | 58.41% | 55.87% | 48.74% | 3.56% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.26% | 55.55% | 48.82% | 56.39% | 38.07% |
| Operating Income | 286.92% | 27.73% | -0.35% | -119.46% | -180.74% |
| Income Before Tax | 207.31% | 560.21% | -21.11% | -1,553.22% | -373.63% |
| Income Tax Expenses | 197.97% | -- | -39.59% | -1,575.96% | -566.71% |
| Earnings from Continuing Operations | 210.14% | 473.81% | -13.87% | -989.70% | -343.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 210.14% | 473.81% | -13.87% | -989.70% | -343.12% |
| EBIT | 286.92% | 27.73% | -0.35% | -119.46% | -180.74% |
| EBITDA | 1,281.86% | 44.60% | 27.41% | -12.55% | -89.15% |
| EPS Basic | 193.59% | 902.61% | -16.50% | -1,592.66% | -376.67% |
| Normalized Basic EPS | 215.61% | 53.46% | -9.21% | -403.01% | -260.39% |
| EPS Diluted | 189.21% | 885.65% | -16.91% | -1,604.93% | -380.73% |
| Normalized Diluted EPS | 210.01% | 49.92% | -9.69% | -406.51% | -262.42% |
| Average Basic Shares Outstanding | 3.45% | 2.66% | 2.66% | 2.33% | 2.76% |
| Average Diluted Shares Outstanding | 8.70% | 5.11% | 3.21% | 1.18% | 1.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.77% | 1.27% | 0.16% | -1.11% | -1.41% |